Status: Not yet recruiting
Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.
Participants needed: 100
Trial details
Biological sex: AllType: ObservationalSponsor: NeuroOne Medical Technologies CorporationUpdated: Apr 22, 2026Duration: 1 Year
Eligibility criteria
Patients diagnosed with drug resistant epilepsy (DRE) [+3]